Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1653 1674
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18499523 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | Non-Final OA | Janssen Biotech, Inc. |
| 18591754 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | Non-Final OA | Novo Nordisk A/S |
| 18426412 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | Non-Final OA | Novo Nordisk A/S |
| 19415046 | PEPTIDE ANALOGS AND METHODS OF USING THE SAME | Non-Final OA | Kallyope, Inc. |
| 18409277 | THERAPEUTIC USES OF DULAGLUTIDE | Non-Final OA | Eli Lilly and Company |
| 18332150 | USE OF CART19 TO DEPLETE NORMAL B CELLS TO INDUCE TOLERANCE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18360393 | POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR | Non-Final OA | Sanofi |
| 17862825 | METHODS AND COMPOSITIONS RELATING TO HOT-START, ONE-STEP, REVERSE TRANSCRIPTION-COUPLED PCR | Final Rejection | Wayne State University |
| 18285753 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHRONIC RENAL DISEASE INCLUDING GLUCAGON DERIVATIVE | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18040869 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18016145 | THERAPEUTIC USE OF COMBINATION COMPRISING TRIPLE AGONISTIC LONG-ACTING CONJUGATE OR TRIPLE AGONIST | Non-Final OA | HANMI PHARM. CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy